Moreover, SARS-CoV-2–specific IgM monoclonal therapeutics are more potent than IgG therapeutics in the treatment of SARS-CoV-2 infection in animal models (77–79), potentially pointing to the possibility that individuals able to selectively expand their OC43-specific IgM or IgG will respond better to COVID-19. The gene discussed is CD40LG; the disease is COVID-19.